<DOC>
	<DOCNO>NCT01709734</DOCNO>
	<brief_summary>A Phase 2 , 2 part trial evaluate safety efficacy galeterone castration resistant prostate cancer ( CRPC ) patient .</brief_summary>
	<brief_title>A 2 Part , Phase 2 Trial Galeterone Treatment Castration Resistant Prostate Cancer</brief_title>
	<detailed_description>This trial split two part . The purpose Part 1 confirm dose target patient population Part 2 expansion dose patient population select Part 1 . For eligible patient , optional extension dose follow completion Part 1 Part 2 trial . Obtaining informed consent screening may perform 28 day prior enrollment . Each patient able receive specify regimen 3 consecutive cycle . Each cycle consist 28 day ( approximately 1 mo. ) . End Cycle 3 visit assessment use determine outcome dosing may continue additional 2 week result assessment obtain . Eligible patient may continue treatment optional extension period follow completion primary part trial .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma prostate 2 . Ongoing androgen blockade demonstrate serum testosterone concentration le 50 ng/dL 3 . Demonstration progression androgen blockade 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 2 1 . Depending upon patient prior treatment follow apply : Prior treatment CYP17 inhibitor AR antagonist ( e.g . abiraterone , TAK700 , ARN509 , ketoconazole* , enzalutamide , galeterone ) Treatment na誰ve Prior treatment CYP17 inhibitor ( e.g . TAK700 , ketoconazole* ) AR antagonist ( e.g . enzalutamide , ARN509 , ) galeterone abiraterone refractory Prior treatment CYP17 inhibitor ( e.g . abiraterone , TAK700 , ketoconazole* ) AR antagonist ( e.g . ARN 509 ) galeterone enzalutamide refractory 2 . Prior chemotherapy ( unless allow study arm ) 3 . Treatment nonsteroidal oral antiandrogens within 4 week enrollment 4 . Prior use chronic systemic glucocorticoid . 5 . Prior radiation therapy within 3 week radionuclide therapy within 8 week enrollment 6 . Prior treatment Alpharadin速 ( Xofigo速 ) 7 . Treatment anti arrhythmia therapy ventricular arrhythmia &lt; 4 week prior enrollment 8 . Treatment Coumadin速 anticoagulant therapy ( except aspirin ) &lt; 4 week prior enrollment 9 . Severe systemic disease active uncontrolled illness . 10 . Abnormal heart function 11 . Liver metastases 12 . Brain metastasis ( unless stable disease &gt; 3 mo . scan without additional CNSdirected therapy ) 13 . The patient know allergy treatment component 14 . Any physical mental condition social situation opinion Investigator may interfere patient 's ability comply trial procedure 15 . History excessive alcohol consumption 16 . Use substance know cause AME</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>prostate cancer CRPC</keyword>
</DOC>